FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jonathan Doorn

Research Profile

Chemicals & Drugs

Living Beings

Physiology

Lipid Peroxidation

Concepts & Ideas

Kinetics

Phenomena

Disorders

Oxidative Stress

Procedures

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Lydia M Vermeer; Colin A Higgins; David L Roman; Jonathan A Doorn
Real-time monitoring of tyrosine hydroxylase activity using a plate reader assay.
Lydia M M Vermeer; Virginia R Florang; Jonathan A Doorn
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
Colin A Higgins; Jonathan A Doorn; Lydia M Vermeer; David L Roman
Expression and purification of recombinant human tyrosine hydroxylase as a fusion protein in Escherichia coli.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jonathan Doorn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lydia M Vermeer; Colin A Higgins; David L Roman; Jonathan A Doorn
Real-time monitoring of tyrosine hydroxylase activity using a plate reader assay.
Analytical biochemistry 2013;432(1):11-5.
2012: Lydia M M Vermeer; Virginia R Florang; Jonathan A Doorn
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
Brain research 2012;1474():100-9.
2012: Colin A Higgins; Jonathan A Doorn; Lydia M Vermeer; David L Roman
Expression and purification of recombinant human tyrosine hydroxylase as a fusion protein in Escherichia coli.
Protein expression and purification 2012;84(2):219-23.
2012: E Danielle Dean; Mahlon R DeLong; Jonathan A Doorn; Jeanne E McKeon; Lydia M Mexas; Gary Miller; Kurt D Pennell; Vin Tangpricha; Natalie L Cápiro; Marian L Evatt
25-Hydroxyvitamin D depletion does not exacerbate MPTP-induced dopamine neuron damage in mice.
PloS one 2012;7(7):e39227.
2011: Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.
Neurotoxicology 2011;32(4):471-7.
2011: David G Anderson; Garry R Buettner; S V Santhana Mariappan; Jonathan A Doorn
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
The Journal of biological chemistry 2011;286(30):26978-86.
2011: Yunden Jinsmaa; Virginia R Florang; Jennifer N Rees; Lydia M Mexas; Laurie L Eckert; Erin M G Allen; David G Anderson; Jonathan A Doorn
Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.
Chemico-biological interactions 2011;192(1-2):118-21.
2010: Erin M G Allen; David G R Anderson; Virginia R Florang; May Khanna; Thomas D Hurley; Jonathan A Doorn
Relative inhibitory potency of molinate and metabolites with aldehyde dehydrogenase 2: implications for the mechanism of enzyme inhibition.
Chemical research in toxicology 2010;23(11):1843-50.
2009: Benjamin J Stewart; James R Roede; Jonathan A Doorn; Dennis R Petersen
Lipid aldehyde-mediated cross-linking of apolipoprotein B-100 inhibits secretion from HepG2 cells.
Biochimica et biophysica acta 2009;1791(8):772-80.
2009: Andrew J Gall; Badal Joshi; Janet Best; Virginia R Florang; Jonathan A Doorn; Mark Blumberg
Developmental emergence of power-law wake behavior depends upon the functional integrity of the locus coeruleus.
Sleep 2009;32(7):920-6.
2009: Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.
Chemical research in toxicology 2009;22(7):1256-63.
2009: Yunden Jinsmaa; Virginia R Florang; Jennifer N Rees; David G Anderson; Stefan Strack; Jonathan A Doorn
Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Chemical research in toxicology 2009;22(5):835-41.
2008: James R Roede; David L Carbone; Jonathan A Doorn; Oleg V Kirichenko; Philip Reigan; Dennis R Petersen
In vitro and in silico characterization of peroxiredoxin 6 modified by 4-hydroxynonenal and 4-oxononenal.
Chemical research in toxicology 2008;21(12):2289-99.
2007: Jennifer N Rees; Virginia R Florang; David G Anderson; Jonathan A Doorn
Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Chemical research in toxicology 2007;20(10):1536-42.
2007: Benjamin J Stewart; Jonathan A Doorn; Dennis R Petersen
Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization.
Chemical research in toxicology 2007;20(8):1111-9.
2007: Brante P Sampey; David L Carbone; Jonathan A Doorn; Derek A Drechsel; Dennis R Petersen
4-Hydroxy-2-nonenal adduction of extracellular signal-regulated kinase (Erk) and the inhibition of hepatocyte Erk-Est-like protein-1-activating protein-1 signal transduction.
Molecular pharmacology 2007;71(3):871-83.
2007: V R Florang; J N Rees; N K Brogden; D G Anderson; T D Hurley; Jonathan A Doorn
Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Neurotoxicology 2007;28(1):76-82.
2006: Jonathan A Doorn; Thomas D Hurley; Dennis R Petersen
Inhibition of human mitochondrial aldehyde dehydrogenase by 4-hydroxynon-2-enal and 4-oxonon-2-enal.
Chemical research in toxicology 2006;19(1):102-10.
2005: David L Carbone; Jonathan A Doorn; Zachary Kiebler; Brian R Ickes; Dennis R Petersen
Modification of heat shock protein 90 by 4-hydroxynonenal in a rat model of chronic alcoholic liver disease.
The Journal of pharmacology and experimental therapeutics 2005;315(1):8-15.
2005: David L Carbone; Jonathan A Doorn; Zachary Kiebler; Dennis R Petersen
Cysteine modification by lipid peroxidation products inhibits protein disulfide isomerase.
Chemical research in toxicology 2005;18(8):1324-31.
2004: David L Carbone; Jonathan A Doorn; Zachary Kiebler; Brante P Sampey; Dennis R Petersen
Inhibition of Hsp72-mediated protein refolding by 4-hydroxy-2-nonenal.
Chemical research in toxicology 2004;17(11):1459-67.
2004: David L Carbone; Jonathan A Doorn; Dennis R Petersen
4-Hydroxynonenal regulates 26S proteasomal degradation of alcohol dehydrogenase.
Free radical biology & medicine 2004;37(9):1430-9.
2004: Jonathan A Doorn; Edmund Maser; Andreas Blum; David J Claffey; Dennis R Petersen
Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal.
Biochemistry 2004;43(41):13106-14.
2004: Dennis R Petersen; Jonathan A Doorn
Reactions of 4-hydroxynonenal with proteins and cellular targets.
Free radical biology & medicine 2004;37(7):937-45.
2003: Jonathan A Doorn; Satish K Srivastava; Dennis R Petersen
Aldose reductase catalyzes reduction of the lipid peroxidation product 4-oxonon-2-enal.
Chemical research in toxicology 2003;16(11):1418-23.
2003: Jonathan A Doorn; Charles M Thompson; Robert B Christner; Rudy Richardson
Stereoselective inactivation of Torpedo californica acetylcholinesterase by isomalathion: inhibitory reactions with (1R)- and (1S)-isomers proceed by different mechanisms.
Chemical research in toxicology 2003;16(8):958-65.
2003: John F Reichard; Jonathan A Doorn; Franz Simon; Melinda S Taylor; Dennis R Petersen
Characterization of multidrug resistance-associated protein 2 in the hepatocellular disposition of 4-hydroxynonenal.
Archives of biochemistry and biophysics 2003;411(2):243-50.
2003: Jonathan A Doorn; Dennis R Petersen
Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal.
Chemico-biological interactions 2003;143-144():93-100.
2002: Jonathan A Doorn; Dennis R Petersen
Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal.
Chemical research in toxicology 2002;15(11):1445-50.
2001: Jonathan A Doorn; Michael Schall; DA Gage; Todd Talley; Charles M Thompson; Rudy Richardson
Identification of butyrylcholinesterase adducts after inhibition with isomalathion using mass spectrometry: difference in mechanism between (1R)- and (1S)-stereoisomers.
Toxicology and applied pharmacology 2001;176(2):73-80.
2001: Jonathan A Doorn; Todd Talley; Charles M Thompson; Rudy Richardson
Probing the active sites of butyrylcholinesterase and cholesterol esterase with isomalathion: conserved stereoselective inactivation of serine hydrolases structurally related to acetylcholinesterase.
Chemical research in toxicology 2001;14(7):807-13.
2000: Jonathan A Doorn; DA Gage; Michael Schall; Todd Talley; Charles M Thompson; Rudy Richardson
Inhibition of acetylcholinesterase by (1S,3S)-isomalathion proceeds with loss of thiomethyl: kinetic and mass spectral evidence for an unexpected primary leaving group.
Chemical research in toxicology 2000;13(12):1313-20.
1999: Scott S Billecke; SL Primo-Parmo; C S Dunlop; Jonathan A Doorn; Bert N La Du; C A Broomfield
Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate.
Chemico-biological interactions 1999;119-120():251-6.
1999: Jonathan A Doorn; RC Sorenson; Scott S Billecke; C Hsu; Bert N La Du
Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase.
Chemico-biological interactions 1999;119-120():235-41.